GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Shattuck Labs Inc.
Shattuck Labs is a biotech company developing innovative immunotherapy drugs. Its stock price is a bet on the success of its unique scientific platform. The chart reflects high volatility associated with clinical trial news.
Share prices of companies in the market segment - Pharma immune
Shattuck Labs is a biopharmaceutical company developing innovative bifunctional proteins for the treatment of cancer and autoimmune diseases. We classify it as "Immune Pharmaceuticals." The chart below illustrates the overall dynamics of this cutting-edge field of medicine.
Broad Market Index - GURU.Markets
Shattuck Labs is an oncology company developing a new class of bifunctional drugs for cancer treatment. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Shattuck shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
STTK - Daily change in the company's share price Shattuck Labs Inc.
Shattuck Labs, Inc.'s daily stock price fluctuations reflect the high volatility inherent in immuno-oncology companies. This metric measures sensitivity to clinical trial data and serves as a key element in assessing risk on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Shattuck Labs, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with STTK's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Shattuck Labs is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Shattuck Labs Inc.
Shattuck Labs, Inc.'s year-over-year performance is a story of developing a new class of bifunctional immuno-oncology drugs. Its 12-month market cap is entirely dependent on early clinical trial data. Positive results could confirm the potential of its unique Agonist Redirected Checkpoint (ARC) platform.
Annual dynamics of market capitalization of the market segment - Pharma immune
Shattuck Labs, Inc. is a clinical-stage biotech company developing a new class of immunotherapy for the treatment of cancer and autoimmune diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shattuck Labs is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Shattuck Labs Inc.
Shattuck Labs is an immuno-oncology company developing dual-functional proteins. Its monthly performance is entirely dependent on progress in its clinical programs. Data presentations at medical conferences are key events shaping investor opinions on the potential of its platform.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Shattuck Labs, Inc. is a biopharmaceutical company developing a new class of bifunctional proteins for the treatment of cancer and autoimmune diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its unique scientific platform, which simultaneously blocks some signals and activates others, is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shattuck Labs is an immuno-oncology company whose stock is immersed in the world of biotech news. Its dynamics are driven by successes in preclinical and clinical trials. The chart shows that the company's monthly fluctuations are largely uncorrelated with the overall market, but are a reaction to company-specific events.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Shattuck Labs Inc.
Shattuck Labs, a clinical-stage biotech developing innovative immuno-oncology drugs, is experiencing high volatility. Weekly stock performance is driven by clinical trial data and partnership news, reflecting the high risks and potential in the fight against cancer.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Shattuck Labs creates innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. This chart compares its data-driven performance with the immunotherapy sector. This provides a key insight into whether its scientific approach stands out from the industry's general clutter.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shattuck Labs is a biotech company developing cancer therapies. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that STTK's performance is almost uncorrelated with the market, driven by its unique development news.
Market capitalization of the company, segment and market as a whole
STTK - Market capitalization of the company Shattuck Labs Inc.
The Shattuck Labs chart is a financial map of a double whammy against cancer. This biotech company's market cap reflects the hopes for its unique platform, which creates molecules that simultaneously block one immune checkpoint and activate another. Its dynamics are a barometer of progress in clinical trials of this innovative immunotherapy.
STTK - Share of the company's market capitalization Shattuck Labs Inc. within the market segment - Pharma immune
Shattuck Labs' market share in the immuno-oncology sector reflects the potential of its unique Agonist Redirected Checkpoint (ARC) platform. Its market share reflects investors' assessment of the company's ability to create innovative dual-functional proteins to combat cancer and autoimmune diseases.
Market capitalization of the market segment - Pharma immune
Shattuck Labs develops innovative bifunctional proteins for the treatment of cancer and autoimmune diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investor confidence in new, sophisticated approaches to modulating the immune system.
Market capitalization of all companies included in a broad market index - GURU.Markets
Shattuck Labs is a biotech company developing dual-functional proteins for the treatment of cancer and autoimmune diseases. Its market capitalization reflects its innovative scientific platform. The chart below shows the economic weight of companies developing new classes of drugs.
Book value capitalization of the company, segment and market as a whole
STTK - Book value capitalization of the company Shattuck Labs Inc.
Shattuck Labs, a biopharmaceutical company, has a book value derived from its capital and laboratory equipment. The chart below shows the financial and scientific resources devoted to developing dual-functional proteins for cancer treatment. This is a visualization of its financial runway.
STTK - Share of the company's book capitalization Shattuck Labs Inc. within the market segment - Pharma immune
Shattuck Labs is a clinical-stage biotech company developing dual-action immunotherapy. Its value lies in its scientific platform and patents. Its tangible asset share will be minimal, typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Pharma immune
Shattuck Labs is an immuno-oncology company. Its value is created in the laboratories where its unique dual agonist platform is being developed. This is a "lightweight" model. The chart below shows the combined physical "weight" of the entire biopharmaceutical industry, which underscores the company's commitment to science.
Book value of all companies included in the broad market index - GURU.Markets
Shattuck Labs' assets include the Agonist Redirected Checkpoint (ARC) scientific platform, which creates unique bidirectional proteins for cancer immunotherapy. The book value reflects the capital invested in this complex and promising technology, which can activate immunity against tumors.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Shattuck Labs Inc.
Shattuck Labs is a biotech company developing dual-functional proteins for the treatment of cancer and autoimmune diseases. Its balance sheet represents cash, and its market capitalization represents the valuation of its unique scientific platform, Agonist Redirected Checkpoint (ARC). The chart shows how the market values this new approach to immunotherapy.
Market to book capitalization ratio in a market segment - Pharma immune
Shattuck Labs is a biotech company developing innovative drugs for the treatment of cancer and autoimmune diseases. Its value lies in its scientific platform. This chart demonstrates how much its market valuation, based on the potential of its unique dual-functional proteins, exceeds the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Shattuck Labs is a biotech company developing innovative dual-functional proteins to treat cancer and autoimmune diseases. This chart shows how the market values this complex scientific platform. Its market capitalization is based not on its assets, but on investors' belief that its unique approach to drug discovery will lead to medical breakthroughs.
Debts of the company, segment and market as a whole
STTK - Company debts Shattuck Labs Inc.
Shattuck Labs is a biopharmaceutical company developing a new class of bifunctional proteins for the treatment of cancer and autoimmune diseases. For a company in clinical development, debt instruments can be a way to finance its innovative, yet capital-intensive, research, as this chart illustrates.
Market segment debts - Pharma immune
Shattuck Labs is a biopharmaceutical company developing bifunctional proteins for the treatment of cancer and autoimmune diseases. Their Agonist Redirected Checkpoint (ARC) platform is unique. The chart illustrates the financial norms for the biotech sector, against which Shattuck funds its complex and expensive research to test the potential of its innovative technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Shattuck Labs Inc.
Shattuck Labs develops innovative bivalent proteins for the treatment of cancer and autoimmune diseases. This is a cutting-edge, but very expensive, area of biotechnology. This chart clearly shows how much of its research the company finances with debt. For investors, this is a key metric for assessing financial strength and risk.
Market segment debt to market segment book capitalization - Pharma immune
Developing bispecific antibodies for immuno-oncology, like Shattuck Labs', is a complex and expensive endeavor. This chart shows the overall debt burden in the biotech sector. It helps us understand how the company's financial strategy, with its unique technology platform, differs from other cancer drug developers.
Debt to book value of all companies in the market
Shattuck Labs develops bifunctional drugs for the treatment of cancer and autoimmune diseases. This is cutting-edge science, requiring significant capital. The chart helps investors understand how the company's debt strategy for funding R&D aligns with or contrasts with overall market trends.
P/E of the company, segment and market as a whole
P/E - Shattuck Labs Inc.
This chart shows the valuation of Shattuck Labs, Inc., a biopharmaceutical company developing innovative drugs for the treatment of cancer and autoimmune diseases. For a clinical-stage company, its value is determined by the potential of its unique scientific platform. The chart serves as a barometer of investor confidence in its developments.
P/E of the market segment - Pharma immune
This metric represents the average valuation for the biotech sector in which Shattuck Labs operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs in immuno-oncology.
P/E of the market as a whole
Shattuck Labs develops unique dual-functional proteins that simultaneously activate the immune response and block signals that suppress it. This is a pioneering approach in immuno-oncology. This chart illustrates the overall interest in biotech. It helps us understand how Shattuck's platform stands out from other immunotherapeutic approaches and how the market views its scientific sophistication and potential.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Shattuck Labs Inc.
Shattuck Labs is a biotech company developing a new class of bifunctional proteins for the immunotherapy of cancer and autoimmune diseases. Its future depends on demonstrating the efficacy of its unique Agonist Redirected Checkpoint (ARC) platform. This chart shows investor expectations for its innovative approach to modulating the immune system to fight disease.
%20P%2FE%20Shattuck%20Labs%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Shattuck-Labs-Inc.&v=1772634500691 "Chart of the company's future (projected) P/E Shattuck Labs Inc.")
Future (projected) P/E of the market segment - Pharma immune
Shattuck Labs develops innovative dual-functional proteins for immunotherapy of cancer and autoimmune diseases. The company's platform enables the creation of molecules that simultaneously act on multiple targets. This chart reflects expectations for the biotech sector, helping to assess how the market values this complex and promising scientific technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772634500737 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Shattuck Labs develops bifunctional proteins for the treatment of cancer and autoimmune diseases. Their platform enables the creation of dual-action drugs. This graph of general expectations reflects investor sentiment toward complex biotech. Market optimism and risk appetite are critical for Shattuck to attract capital for its innovative and long-term research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772634500766 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Shattuck Labs Inc.
Shattuck Labs is a biotech company developing dual-functional proteins to treat cancer and autoimmune diseases. This chart reflects the financial costs of developing this innovative platform. Profit is a long-term goal, and current metrics demonstrate investments in advancing its unique drug candidates through clinical trials.
Profit of companies in the market segment - Pharma immune
OneMedNet Corporation operates a platform for sharing and analyzing anonymized medical data for research purposes. Profitability depends on the value of this data for pharmaceutical companies. This graph illustrates how real-world data (RWD) is becoming a key asset in medicine, creating a new market for companies that can aggregate and analyze it.
Overall market profit
Shattuck Labs is a biotech company developing innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. Like other companies in clinical development, its future depends on science. The overall corporate profitability chart provides a backdrop for assessing how the path of such companies differs from traditional businesses.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Shattuck Labs Inc.
Shattuck Labs is a biotech company developing a new class of bifunctional proteins for the treatment of cancer and autoimmune diseases. Its revenue outlook is long-term and depends on the success of clinical trials. This chart shows how analysts assess the potential of Shattuck's unique scientific platform and its ability to create innovative drugs.
%20profit%20of%20the%20company%20Shattuck%20Labs%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Shattuck-Labs-Inc.&v=1772634500897 "Graph of future (projected) profit of the company Shattuck Labs Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Shattuck Labs develops innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. The company's technology enables simultaneous targeting of multiple immune pathways. This chart shows profitability forecasts for the biotech sector. It reflects the market's confidence in the new generation of immunotherapy, which promises to be even more effective.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772634500936 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Shattuck Labs develops innovative, dual-action immuno-oncology therapies. This is cutting-edge science, requiring significant investment in R&D. The total revenue projections reflected here provide an investment backdrop. During periods of economic optimism, biotech companies like Shattuck find it easier to raise capital for research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772634500942 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Shattuck Labs Inc.
Shattuck Labs is a biotech company developing a new class of bifunctional proteins for the treatment of cancer and autoimmune diseases. Its revenue is generated through partnerships with major pharmaceutical companies. The chart shows how the market evaluates the potential of its unique scientific platform, rather than its current financial performance, which places a premium on future breakthroughs.
P/S market segment - Pharma immune
Shattuck Labs, Inc. is a clinical-stage biopharmaceutical company developing innovative bifunctional proteins for the treatment of cancer and autoimmune diseases. Its Agonist Redirected Checkpoint (ARC)® platform is unique. This chart shows the average valuation in the sector, allowing one to assess the market's perception of the revenue potential of Shattuck's science.
P/S of the market as a whole
Shattuck Labs develops innovative bivalent proteins for the treatment of cancer and autoimmune diseases. The company's technology allows for simultaneous targeting of multiple immune pathways. This chart, reflecting the average real market revenue estimate, clearly highlights the difference between investing in breakthrough science and investing in companies with existing sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Shattuck Labs Inc.
Shattuck Labs develops innovative dual-functional proteins for immunotherapy of cancer and autoimmune diseases. This chart shows how investors assess the future potential of its scientific platform. The assessment is based on expectations of successful clinical trials, which could lead to the development of a new class of drugs.
%20P%2FS%20Shattuck%20Labs%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Shattuck-Labs-Inc.&v=1772634501099 "The graph of the company's future (projected) P/S Shattuck Labs Inc.")
Future (projected) P/S of the market segment - Pharma immune
Shattuck Labs develops innovative bifunctional proteins for the treatment of cancer and autoimmune diseases. Its Agonist Redirected Checkpoint (ARC) platform combines two functions in a single molecule. The chart shows how the market estimates Shattuck's future sales, reflecting confidence in the potential of its unique scientific approach to immunotherapy.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772634501113 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Future revenue expectations in biotech hinge on new approaches to cancer immunotherapy. Shattuck Labs creates unique dual-functional proteins that simultaneously block the immune system's "brakes" and activate its "accelerators." Their sophisticated scientific platform reflects the market's belief that combined approaches will lead to breakthroughs in cancer treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772634501145 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Shattuck Labs Inc.
Shattuck Labs is a clinical-stage biopharmaceutical company developing a new class of immunotherapy drugs for cancer and autoimmune diseases. Its revenue at this stage comes from payments from strategic partnerships, not sales. This chart illustrates the financial aspects of research and development in anticipation of commercial success.
Sales of companies in the market segment - Pharma immune
Shattuck Labs is developing a new class of bifunctional proteins for cancer immunotherapy. Their drugs simultaneously block checkpoints and activate the immune response. This chart reflects overall revenue in the immunology pharmaceutical sector. It highlights the intense competition and demand for more potent approaches, where Shattuck offers its innovative platform.
Overall market sales
Shattuck Labs is a clinical-stage biopharmaceutical company developing a new class of bifunctional proteins for cancer immunotherapy. Its success depends entirely on the results of clinical trials. This general economic climate affects the overall availability of capital for biotech companies conducting expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Shattuck Labs Inc.
Shattuck Labs is a biotech company developing innovative dual-functional proteins for immunotherapy of cancer and autoimmune diseases. Its future depends on the success of clinical trials. The chart shows analysts' speculative revenue forecasts, which are betting on a breakthrough in immuno-oncology and partnerships with pharma giants.
%20sales%20of%20the%20company%20Shattuck%20Labs%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Shattuck-Labs-Inc.&v=1772634501385 "Schedule of future (projected) sales of the company Shattuck Labs Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Shattuck Labs is a biopharmaceutical company creating unique dual-functional proteins for the treatment of cancer and autoimmune diseases. Its Agonist Redirected Checkpoint (ARC) platform is innovative. This chart displays projected sales for the entire immunological pharmaceutical segment, demonstrating overall growth expectations for this cutting-edge field of medicine.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772634501406 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Shattuck Labs develops bifunctional proteins for the treatment of cancer and autoimmune diseases. The company is in early clinical trials, and its valuation is determined by the potential of its scientific platform. This overall economic activity profile influences investor risk appetite, which determines the funding of such innovative biotech startups.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772634501452 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Shattuck Labs Inc.
Shattuck Labs is a biotech company developing innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. This metric reflects its financial performance during the R&D phase and demonstrates the level of investment in clinical trials required to validate the efficacy of its unique scientific platform.
Market segment marginality - Pharma immune
Shattuck Labs is a biopharmaceutical company developing bifunctional proteins for the treatment of cancer and autoimmune diseases. Profitability is a future goal, dependent on the success of its Agonist Redirected Checkpoint (ARC) platform. This metric reflects the company's operational structure and investment in this cutting-edge scientific platform.
Market marginality as a whole
Shattuck Labs is a biopharmaceutical company developing innovative bifunctional proteins for the treatment of cancer and autoimmune diseases. Their Agonist Redirected Checkpoint (ARC) platform is unique. Their valuation is dependent on research progress. This overall profitability curve is influenced by the overall investment climate in the immuno-oncology sector.
Employees in the company, segment and market as a whole
Number of employees in the company Shattuck Labs Inc.
Shattuck Labs is a biotech company developing innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. At the clinical stage, its primary asset is science. This graph shows the growth of its research team, whose growth is directly related to the advancement of its unique Agonist Redirected Checkpoint (ARC) platform.
Share of the company's employees Shattuck Labs Inc. within the market segment - Pharma immune
Shattuck Labs creates unique dual-functional proteins to treat cancer and autoimmune diseases. This chart shows the percentage of leading immunologists and protein engineers interested in its innovative platform. The Shattuck team is at the forefront of developing the next generation of immunotherapies.
Number of employees in the market segment - Pharma immune
Shattuck Labs, Inc. is a biotechnology company developing innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. This chart shows overall employment in the immunology research sector. It illustrates the complexity and high scientific level of research aimed at simultaneously targeting multiple biological targets.
Number of employees in the market as a whole
Shattuck Labs is a biotech company developing a new class of drugs for the immunotherapy of cancer and autoimmune diseases. Its Agonist Redirected Checkpoint (ARC) platform is unique. This overall staffing chart reflects the contributions of these innovators, with each new research fellow bringing us closer to more effective and safer treatments for patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Shattuck Labs Inc. (STTK)
Shattuck Labs, Inc. is an innovative biotech company developing dual-functional proteins to treat cancer and autoimmune diseases. This chart demonstrates the market's high valuation of its scientific potential. As with most biotech companies, the company's market capitalization per employee is very high, as investors see value in its unique platform and development pipeline.
%20of%20the%20company%20Shattuck%20Labs%20Inc.%20(STTK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Shattuck-Labs-Inc.-STTK&v=1772634501624 "Chart of market capitalization per employee (in thousands of dollars) of the company Shattuck Labs Inc. (STTK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Shattuck Labs is a biotech company focused on immuno-oncology, creating unique dual-functional proteins. Their core asset is their scientific platform. This chart shows how investors view their innovative approach. Their high market capitalization per employee suggests high expectations for their developments and the potential to create a new class of drugs.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772634501651 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Shattuck Labs, Inc. is a clinical-stage biopharmaceutical company developing a new class of drugs for the treatment of cancer and autoimmune diseases. Its valuation is based on the potential of its unique scientific platform. This metric reflects how investors value breakthrough research that has the potential to create entirely new therapeutic approaches.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772634501672 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Shattuck Labs Inc. (STTK)
Shattuck Labs is a biotech R&D company developing innovative dual-functional proteins for the treatment of cancer and autoimmune diseases. This is cutting-edge science. This metric demonstrates their capital burn rate, reflecting the net loss (research costs) per scientist working on their platform.
%20Chart%20Shattuck%20Labs%20Inc.%20(STTK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Shattuck-Labs-Inc.-STTK&v=1772634501700 "Company Profit Per Employee (in thousands of dollars) Chart Shattuck Labs Inc. (STTK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Shattuck Labs is a clinical-stage biotech company developing innovative dual-functional proteins for cancer treatment. As with other R&D firms, this timeline is a goal for the future. Currently, all value lies in the intellectual potential of their scientific team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772634501719 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Shattuck Labs (STTK) is a biotech company developing a novel platform of "dual-functional" proteins for the treatment of cancer and autoimmune diseases. Their focus is complex immuno-oncology. This metric reflects the R&D phase: the company invests in its scientists, resulting in negative profits before commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772634501783 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Shattuck Labs Inc. (STTK)
For Shattuck Labs, a biopharmaceutical company developing dual-functional proteins to treat cancer and autoimmune diseases, this chart shows the efficiency of its scientific platform. Revenue per employee is generated primarily through collaborations with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Shattuck-Labs-Inc.-STTK&v=1772634501801 "Sales chart per company employee Shattuck Labs Inc. (STTK)")
Sales per employee in the market segment - Pharma immune
Shattuck Labs is a clinical-stage biopharmaceutical company developing dual-functional proteins for the treatment of cancer and autoimmune diseases. This R&D activity is complex. This metric reflects the average revenue per employee for the segment. It allows us to assess how productive their scientific team is in advancing their unique developments compared to competitors.
Sales per employee for the market as a whole
Shattuck Labs (STTK) is a clinical-stage biopharmaceutical company developing innovative immunotherapies (dual-functional proteins) for the treatment of cancer. Currently, its staff consists entirely of researchers. This metric is critical for STTK: it's at zero. Its future growth will signal the success of their R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Shattuck Labs Inc. (STTK)
Shattuck Labs develops innovative bifunctional proteins for the treatment of cancer and autoimmune diseases. This is a complex and highly competitive field of biotechnology. This chart reflects investor bets that this complex scientific platform will face challenges in clinical trials related to safety or efficacy.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Shattuck-Labs-Inc.-STTK&v=1772634501906 "Short Shares Chart for the Company Shattuck Labs Inc. (STTK)")
Shares shorted by market segment - Pharma immune
Shattuck Labs (STTK) is a biopharmaceutical company developing innovative dual-functional proteins (checkpoint inhibitors) for the treatment of cancer and autoimmune diseases. This chart shows the aggregate bearish bets on the immuno-oncology sector. It reflects the high investor skepticism regarding new, complex platforms and the intense competition in this field.
Shares shorted by the overall market
Shattuck Labs (STTK) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like STTK in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Shattuck Labs Inc. (STTK)
Shattuck Labs is a biotech company working in the field of immuno-oncology. This is a high-risk bet on their R&D platform. This chart measures the extremes of speculative sentiment. It shows when the stock is "overheated" (overbought) on positive news from the lab or "oversold" due to long-term R&D.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Shattuck-Labs-Inc.-STTK&v=1772634501940 "RSI 14 indicator chart for the company's stock Shattuck Labs Inc. (STTK)")
RSI 14 Market Segment - Pharma immune
Shattuck (STTK) is a "biotech" and an "immunity engineer." Their platform (Agonist Redirected Checkpoint, ARC) creates "two-armed" proteins that simultaneously "press the gas" and "release the brake" on cancer immunity. The "Pharma immune" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is STTK's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Shattuck Labs (STTK) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast STTK (Shattuck Labs Inc.)
Shattuck Labs develops "bifunctional" proteins (ARC platform) that simultaneously block checkpoint inhibitors (PD-L1) and activate immune cells (TNF) to fight cancer. This chart shows the speculative average price target from analysts based on their belief in this innovative R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-STTK-Shattuck-Labs-Inc.&v=1772634501993 "A chart showing analyst consensus forecasts for the expected stock price. STTK (Shattuck Labs Inc.)")
The difference between the consensus estimate and the actual stock price STTK (Shattuck Labs Inc.)
Shattuck Labs is a biotech company developing innovative "bi-functional" proteins (the Agonist Redirected Checkpoint (ARC) platform) for cancer treatment. This chart shows the gap between the market valuation and analyst target price. It highlights the potential experts see in this complex but promising immunotherapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-STTK-Shattuck-Labs-Inc.&v=1772634502005 "A chart showing the difference between the consensus forecast and the actual stock price. STTK (Shattuck Labs Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Shattuck Labs (STTK) is a biotech company developing dual immunomodulators (the Agonist Redirected Checkpoint (ARC) platform). These are new weapons for cancer immunotherapy. This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe in R&D innovation in oncology.
Analysts' consensus forecast for the overall market share price
Shattuck Labs is a biotech company developing an innovative platform (ARC) that creates "two-way" proteins for cancer immunotherapy. This chart shows the overall risk appetite. For Shattuck, a high-risk clinical-stage company, overall market optimism is critical to attracting the capital needed to fund long-term research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Shattuck Labs Inc.
Shattuck (STTK) is a clinical-stage biotech focused on immuno-oncology. Their signature product is dual (bifunctional) proteins that simultaneously block cancer (checkpoint) and activate immunity. This chart represents pure R&D betting. Its valuation reflects the market's faith in their complex but powerful scientific platform and early clinical trial data.
AKIMA Market Segment Index - Pharma immune
Shattuck Labs develops innovative dual-functional proteins (Agonist Redirected Checkpoint, ARC) that simultaneously inhibit some targets and activate others to fight cancer. This chart shows the average index for the immunopharmaceutical sector. It helps investors assess how Shattuck's scientific approach compares to the average.
The AKIM Index for the overall market
Shattuck Labs is a biotech company developing bifunctional fusion proteins (ARCs) for immunotherapy of cancer and autoimmune diseases. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for funding this cutting-edge scientific platform and assessing its potential.
